Literature DB >> 3490533

Idiotype variant cell populations in patients with B cell lymphoma.

W L Carroll, J N Lowder, R Streifer, R Warnke, S Levy, R Levy.   

Abstract

Using isolated idiotype (Id) protein we generated panels of antibodies in two patients with follicular lymphoma, one of whom had never received prior chemo-or radiotherapy. Flow cytometry and frozen section tissue staining of tumor with these monoclonal antibodies (mAb) revealed multiple subpopulations within each tumor. Individual mAb stained between 7% and 83% of surface Ig+ cells in the tumor samples. These subpopulations were overlapping and no single antibody recognized all the tumor cells. However, combinations of antibodies seemed to capture total tumor in both cases. In some instances, the percentage of tumor stained by a single mAb varied over time, and differed between lymph nodes sampled at the same time. Because a single species of Id protein was used to generate mAb in each case, it appears that the antibodies were directed against idiotopes variably shared by different populations within each tumor, and this was confirmed by crossblocking studies. Tumor cells from one patient were fused to a nonsecreting heteromyeloma line K6H6/B5, and most of the resulting hybrids secreted Id protein. Four mAb were used to screen the Id proteins secreted by these hybrids, and 11 different variants (16 maximal) were found. Southern blot analysis of rearranged Ig genes was done in two hybrids and biopsy material. Identically rearranged light-chain genes were seen but it appeared as though extensive somatic variation had occurred in heavy chain genes. These studies indicate that: striking Id variation can exist at diagnosis in untreated patients, the percentage of tumor represented by an individual variant may change with time and may differ between tumor sampled from different anatomical locations, and somatic variation appears to be responsible for the observed heterogeneity. Although this degree of variation makes anti-Id antibody therapy more difficult, appropriate combinations of mAb should be more efficacious than single antibodies in such cases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490533      PMCID: PMC2188459          DOI: 10.1084/jem.164.5.1566

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Mouse x human heterohybridomas as fusion partners with human B cell tumors.

Authors:  W L Carroll; K Thielemans; J Dilley; R Levy
Journal:  J Immunol Methods       Date:  1986-05-01       Impact factor: 2.303

2.  Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.

Authors:  G T Stevenson; E V Elliott; F K Stevenson
Journal:  Fed Proc       Date:  1977-08

Review 3.  Monoclonal antibodies reveal the structural basis of antibody diversity.

Authors:  J L Teillaud; C Desaymard; A M Giusti; B Haseltine; R R Pollock; D E Yelton; D J Zack; M D Scharff
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

Review 4.  NIH conference. Molecular genetic analysis of human lymphoid neoplasms. Immunoglobulin genes and the c-myc oncogene.

Authors:  T A Waldmann; S J Korsmeyer; A Bakhshi; A Arnold; I R Kirsch
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

5.  Somatic mutation gains its place among the generators of diversity.

Authors:  D Baltimore
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

6.  Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization.

Authors:  R Levy; J Dilley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

7.  Studies on the clonal origin of human B cell leukemia using monoclonal anti-idiotype antibodies.

Authors:  M Mayumi; H Kubagawa; G A Omura; W E Gathings; J F Kearney; M D Cooper
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

8.  Immunoglobulin secretion by mouse X human hybridomas: an approach for the production of anti-idiotype reagents useful in monitoring patients with B cell lymphoma.

Authors:  S Brown; J Dilley; R Levy
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

9.  Frequent biclonality and Ig gene alterations among B cell lymphomas that show multiple histologic forms.

Authors:  M H Siegelman; M L Cleary; R Warnke; J Sklar
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

10.  Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin.

Authors:  S H Clarke; K Huppi; D Ruezinsky; L Staudt; W Gerhard; M Weigert
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

View more
  16 in total

1.  Tumorigenesis mediated by an antigen receptor.

Authors:  H M Jäck; G Beck-Engeser; G Lee; D Wofsy; M Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

2.  Immunoglobulin idiotype expression in reactive lymphoid tissues and B-cell lymphomas.

Authors:  M Shiota; K Kitamura; M Noda; Y Kawanishi; S Hart; R A Miller; S Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Use of idiotype markers for cellular detection of monoclonal rheumatoid factor.

Authors:  C G Winearls; J G Sissons
Journal:  Springer Semin Immunopathol       Date:  1988

Review 4.  Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.

Authors:  Scott A Smith; James E Crowe
Journal:  Microbiol Spectr       Date:  2015-02

5.  High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia.

Authors:  T J Kipps; S Fong; E Tomhave; P P Chen; R D Goldfien; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

7.  Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.

Authors:  Bindu Varghese; Adam Widman; James Do; Behnaz Taidi; Debra K Czerwinski; John Timmerman; Shoshana Levy; Ronald Levy
Journal:  Blood       Date:  2009-09-17       Impact factor: 22.113

8.  An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors:  Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal:  J Immunol Methods       Date:  2008-05-05       Impact factor: 2.303

9.  Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

Authors:  A A McCormick; S Reddy; S J Reinl; T I Cameron; D K Czerwinkski; F Vojdani; K M Hanley; S J Garger; E L White; J Novak; J Barrett; R B Holtz; D Tusé; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-21       Impact factor: 11.205

10.  Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia.

Authors:  J Bird; N Galili; M Link; D Stites; J Sklar
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.